Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 18, 2020 - Issue 4
Submit an article Journal homepage
494
Views
6
CrossRef citations to date
0
Altmetric
Drug Profile

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

Arturo CicculloInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-5941-883XView further author information
ORCID Icon,
Gianmaria BaldinInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy;Mater Olbia Hospital, Olbia, ItalyORCID Iconhttps://orcid.org/0000-0003-4623-9976View further author information
ORCID Icon,
Alberto BorghettiUOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyView further author information
&
Simona Di GiambenedettoInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy;UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyCorrespondence[email protected]
View further author information
Pages 279-292 | Received 30 Dec 2019, Accepted 11 Feb 2020, Published online: 18 Feb 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Alemu Birara Zemariam, Yabibal Berie Tadesse & Abebe Tarekegn Kassaw. (2023) Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study. HIV/AIDS - Research and Palliative Care 15, pages 271-278.
Read now

Articles from other publishers (5)

Mingli Zhong, Chen Chen, Yue Hu, Meiyin Zou, Liting Yan, Jinlong Huang, Ru Lv, Yifan Su, Mingxue Qi, Zi Ye, Xueyu Pei, Ping Ma & Hongxia Wei. (2022) Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1–Infected Patients: A Multicenter Cohort Study in China. JAIDS Journal of Acquired Immune Deficiency Syndromes 91:S1, pages S42-S50.
Crossref
A Borghetti, M Alkhatib, A Dusina, L Duca, V Borghi, M Zazzi & S Di Giambenedetto. (2021) Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study. Journal of Antimicrobial Chemotherapy 77:3, pages 740-746.
Crossref
Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, Filippo Lagi, Alessandra Latini, Gabriella d’Ettorre, Letizia Oreni, Paolo Fusco, Amedeo Capetti, Massimiliano Fabbiani, Andrea Giacomelli, Alessandro Grimaldi, Giordano Madeddu, Gaetana Sterrantino, Cristina Mussini & Simona Di Giambenedetto. (2022) Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. Viruses 14:1, pages 163.
Crossref
Alberto Borghetti, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Alex Dusina, Massimiliano Fabbiani, Stefano Rusconi, Maurizio Zazzi, Cristina Mussini & Simona Di Giambenedetto. (2021) Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases 8:7.
Crossref
Gianmaria BaldinArturo CicculloFrancesca LombardiAnna D'AngelilloAlex DusinaArianna EmiliozziDamiano FarinacciDavide MoscheseChiara PicarelliAlberto BorghettiSimona Di Giambenedetto. (2021) Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. AIDS Research and Human Retroviruses 37:6, pages 429-432.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.